Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-12-10

Clinical Trial Update: Effect of Age on Latanoprost 0.005% in Patients With Glaucoma [Phase 4]

View source ↗

Summary

This Phase 4 trial from Yale evaluated whether age impacts the effectiveness of latanoprost 0.005% in glaucoma patients, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xalatan (latanoprost)

Snippet

Sponsor: Yale University | Conditions: Glaucoma | Phase 4 | Status: COMPLETED | Results posted: 2012-12-10